A Phase II Study of Talimogene laherparepvec Followed by Talimogene laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas Cutaneous Squamous Cell Carcinoma Merkel Cell Carcinoma and Other Rare Skin Tumors

Brief description of study

The purpose of the study is to determine the safety and efficacy of talimogene laherparepvec monotherapy followed by combination therapy with nivolumab (NIVO) for patients who have Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors. We want to know if talimogene laherparepvec alone works better or in combination with nivolumab after patients respond to therapy.

Clinical Study Identifier: s20-00580
ClinicalTrials.gov Identifier: NCT02978625
Principal Investigator: Janice Mehnert.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.